Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb;54(2):237-41.
doi: 10.1136/gut.2004.045294.

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

J Cosnes  1 , I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P Gendre
Affiliations

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

J Cosnes et al. Gut. 2005 Feb.

Erratum in

  • Gut. 2005 May;54(5):734

Abstract

Background/aim: Immunosuppressants are now used much earlier in the course of Crohn's disease; however their effect on the natural history of the disease, especially on the need for surgery, is not known. The aim of this study was to assess the evolution of the need for surgery in Crohn's disease during the last 25 years.

Patients and methods: The medical charts of 2573 patients were reviewed retrospectively. The use of immunosuppressants (azathioprine or methotrexate), the need for intestinal resection, and the occurrence of intestinal complications were assessed using Kaplan-Meier analysis in five consecutive cohorts of patients defined by the date of diagnosis of Crohn's disease (1978-82; 1983-87; 1988-92; 1993-97; 1998-2002).

Results: In 565 patients seen in the authors' unit within the first three months after diagnosis, characteristics of Crohn's disease at diagnosis did not differ from one cohort to another. The five year cumulative probability to receive immunosuppressants increased from 0 in the 1978-82 cohort to 0.13, 0.25, 0.25, and 0.56 in the 1983-87, 1988-92, 1993-97, and 1998-2002 cohorts, respectively (p<0.001). Concomitantly, the cumulative risk of intestinal resection remained unchanged (from 0.35 to 0.34 at five years; p=0.81). The cumulative risk of developing a stricturing or a penetrating intestinal complication remained also unchanged. Similar results were obtained in the 2008 patients seen during the same period who were referred to us more than three months after diagnosis.

Conclusion: Although immunosuppressants have been used more frequently over the last 25 years, there was no significant decrease of the need for surgery, or of intestinal complications of Crohn's disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of the cumulative risk of receiving immunosuppressants in five chronologic cohorts of patients with Crohn’s disease.
Figure 3
Figure 3
Evolution of the annual rate of intestinal resections from 1978–2003 in 2573 patients with Crohn’s disease. The numbers above the columns indicate the number of patients at risk for intestinal resection at the beginning of the year.
See this image and copyright information in PMC

References

    1. Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 2001;52:299–318. - PubMed
    1. Lennard-Jones JE. Azathioprine in the treatment of Crohn’s disease. Proc R Soc Med 1972;65:291–3. - PMC - PubMed
    1. Feagan BG. Standard immunosuppression in IBD: current practice. Acta Gastroenterol Belg 2001;64:182–8. - PubMed
    1. Korelitz BI, Present DH. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital. Mt Sinai J Med 1996;63:191–201. - PubMed
    1. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132–42. - PubMed

MeSH terms